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ABSTRACT 
Aim: The goal of this study was to compare asthma 
treatment guidance based on bronchial hyper-re- 
sponsiveness to mannitol, spirometry or exhaled ni-
tric oxide (FeNO) in stable asthmatic children. Meth-
ods: 60 stable allergic asthmatic children aged 7 to 16 
years on a low to medium dose treatment with in- 
haled corticosteroids (ICS) were recruited to a double 
blind randomised controlled trial. At study entry 
(visit 1), the following was assessed: FeNO, spirometry, 
bronchial hyper-responsiveness to mannitol (MDP- 
test), quality of life (paediatric asthma quality-of-life 
questionnaire; PAQLQ) and asthma control (asthma 
control test; ACT). Subjects were randomly assigned 
to one of three groups and treatment was modified by 
a blinded respiratory physician according to the test 
results of visit 1: ICS dose was doubled when FeNO 
was >22 ppb (group 1), in case of a positive MDP-test 
(group 2) or when FEV1 was <80% of a predicted one 
(group 3), respectively, or remained unchanged for 
the remaining subjects. After 3 months (visit 2), the 
subjects were reassessed and all tests were repeated. 
Results: 48 children successfully completed the study. 
At the first visit, 8 out of 16 (50%) children in group 1 
showed a FeNO > 22 ppb, 8 children out of 16 (50%) 
in group 2 showed a positive MDP-test and 3 children 
out of 16 (18.7%) in group 3 had a FEV1 < 80% of 
that predicted and had their ICS-dose doubled. In 
group 1, FeNO decreased significantly after the in-
tervention (p = 0.005), whereas the self-administered 
and the interviewer-administered PAQLQ (p = 0.02 
resp. p = 0.033) as well as the ACT (p = 0.031) in-
creased. Neither the number of children with a posi-
tive mannitol challenge nor spirometric results 
changed significantly. In group 2 and group 3, there 
were no significant changes in none of the assessed 
parameters. Conclusion: In this small pragmatic 
double blind randomised controlled study, we showed 
that ICS dose modification based on FeNO led to in-
creased quality of life and enhanced asthma control, 
and to a reduction in airway inflammation and was 
superior to treatment modifications based on bron-
chial hyper-responsiveness to mannitol or on FEV1.  
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1. INTRODUCTION 
The goal of asthma management as described in national 
and international guidelines is optimal asthma control [1]. 
Despite highly effective therapy options being available, 
this goal is only achieved in a minority of asthmatic 
children [2-4]. Up to 80% of children suffer from occa- 
sional asthma symptoms, more than 40% from limitation 
in their physical activity and/or nocturnal awakening, 
and for more than 50%, parents are worried about their 
asthmatic child [5]. The reasons for this lack in achieving 
asthma control are likely to be multiple, one being that 
objective parameters of disease activity are not evaluated 
on a regular base to guide therapy [2]. Several instru- 
ments have been developed to evaluate asthma control 
including the Asthma Control Questionnaire (ACQ) [6], 
the Asthma Control Scoring System (ACSS) [7], and the *Corresponding author. 
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Asthma Control Test (ACT) [8], the latter being adapted 
for its use in children [9]. For applying these instruments 
including the GINA [1] guidelines, caregivers have to 
rely on the report of symptoms by the child and/or par- 
ents. One possible reason for not achieving the goals 
stated in guidelines may be the poor perception of 
asthma control by parents and patients [5,10]. There is an 
apparent tendency of parents and children with signifi- 
cant symptoms to inappropriately report good control 
[5]. 
It is therefore likely that the measurement of patho- 
physiological mechanisms of asthma, hence, the meas- 
urement of objective parameters of disease activity such 
as airway obstruction, bronchial hyper-responsiveness 
(BHR), and airway inflammation [4,11] may be helpful 
to guide treatment. There are, however, still many open 
questions. Several studies have shown only a weak or no 
correlation between objective parameters and asthma 
symptoms. No correlation was shown between FEV1 and 
individual symptom scores or clinical disease severity 
scores in asthmatic children, whereas a weak correlation 
has been found for the ratio FEV1/FVC and symptom 
scores [12,13]. In addition, only 34% of asthmatic chil- 
dren show a significant correlation between BHR to 
methacholine and symptom scores [11]. One explanation 
of this lack in correlation may be the fact that lung func- 
tion and BHR show a slow response to modification by 
inhaled corticosteroids and may therefore not be ideal 
tools for short term therapy guidance [14,15]. For the 
above-mentioned reasons, it would be beneficial to have 
additional objective parameters for the guidance of 
treatment. Ideally, such parameters reflect the patho- 
physiology of allergic asthma, correlate closely to symp- 
toms and show a fast response on changing disease con- 
trol. 
The measurement of fractional exhaled nitric oxide 
(FeNO) has been shown to be helpful in the assessment 
of asthma in children and adults, mainly in treatment 
monitoring. Regular determination of FeNO can be help- 
ful in observing adherence to treatment and in predicting 
exacerbations as well as the course of asthma [10,16-23]. 
FeNO measurements are simple to perform, reproducible 
and have a good acceptance by healthy and asthmatic 
adults and children [24]. In recent years, several publica- 
tions have shown that FeNO is an efficient tool for diag- 
nosing allergic asthma [23,25]. In addition, FeNO has 
achieved an important role in predicting clinical outcome 
in terms of steroid response, exacerbations and long-term 
outcomes [18-22]. Furthermore, it has been reported that 
FeNO can be used as a marker for asthma control [26,27] 
and that FeNO has a fast response to treatment modifica- 
tion [14,28]. Several studies have assessed the use of 
FeNO as an alternative method to modify ICS treatment 
based on symptoms and/or pulmonary function in asth- 
matic children and adults with conflicting results [17, 
29-33].  
Mannitol dry powder (MDP) challenge is an indirect 
bronchial provocation test, which is well studied in 
adults and is used more and more in the assessment of 
childhood asthma. A recent study has proven that the 
MDP challenge is safe and feasible in asthmatic children 
[34]. However, only few studies have investigated the 
use of mannitol as diagnostic tool to evaluate BHR. 
Anderson and Lipworth evaluated relationships between 
mannitol BHR and methacholine challenge as well as 
measures of airway inflammation (FeNO and salivary 
eosinophilic cationic protein) in adult persistent asthmat- 
ics receiving inhaled corticosteroids [35]. The authors 
observed a good correlation between mannitol, meth- 
acholine and FeNO and concluded that mannitol chal- 
lenge adequately reflects bronchial inflammation. Inter- 
estingly, a recent study suggested that FeNO is sensitive 
and specific for accurately predicting BHR, measured by 
the response to inhaled mannitol, in steroid-naïve ado- 
lescents and young adults, revealing an optimal cut-off at 
25 ppb [36]. The authors concluded that inhaled mannitol 
challenge does not add additional diagnostic information 
when FeNO values are low. Moreover, mannitol has 
been shown to be less sensitive than methacholine to 
predict BHR in youth athletes with exercise-induced 
bronchoconstriction, pointing to a possible influence of 
asthma phenotype in the value of diagnostic methods for 
BHR [37]. 
Compared to studies addressing BHR, data on the 
usefulness of mannitol challenge in guiding treatment in 
asthmatic children are even scarcer. A recent study by 
Kersten et al. showed that mannitol PD15 did not sig- 
nificantly change after stepping down ICS treatment in 
stable asthmatic children [38]. Similarly, the STAMINA 
trial in an adult cohort with persistent asthma demon- 
strated a higher exposure to ICS when treatment was 
guided by mannitol compared to a conventional strategy 
based on symptoms, reliever use, and lung function, in 
spite of an equivocal number of severe asthma exacerba- 
tions [39]. Taken together, to date it is still unclear which 
objective parameter is the most useful to guide treatment 
in children with asthma. Moreover, there are discrepan- 
cies to which stage objective measures of asthma control 
correlate with subjective symptoms reporting, hence to 
most frequently used tools for assessment of asthma con- 
trol, such as the ACT. A recent study confirms and ex- 
pands the concept that C-ACT is complementary to, but 
not a substitute for other markers of disease control in 
asthmatic children [40]. 
The aim of this study was to compare treatment guid- 
ance based on bronchial hyper-responsiveness to manni- 
tol, FeNO and spirometry in stable children with allergic 
asthma. 
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2. METHODS 
Subjects. 60 children with stable allergic asthma aged 
between 7 to 16 years were recruited. All children were 
on a low to medium dose treatment with inhaled corti- 
costeroids (ICS; 200 - 400 μg budesonide equivalent per 
day). A total of 48 children completed the study (27 boys, 
21 girls) and were included in the final analysis. Children 
were recruited from the asthma clinics of the Alpine 
Children’s Hospital, Davos and the department of paedi- 
atrics of HFR Fribourg, Switzerland.  
Exclusion criteria included the following: children 
with a history of other respiratory disease, such as cystic 
fibrosis or neonatal lung disease, and acute upper airway 
infection within the last 3 weeks or asthma exacerbation 
within the last 3 months requiring systemic steroids. 
The study was approved by the local ethics committee. 
Informed written consent was obtained from the parents 
or guardians of all subjects. 
Study Design. Double-blinded, randomized controlled 
trial assessing three different strategies to adapt ICS 
treatment in children with allergic asthma, consisting of 
two consecutive clinical visits three months apart. At 
each visit the following assessments were performed. 
Fractional exhaled nitric oxide (FeNO) was meas- 
ured using an electrochemistry-based analyser (NIOX 
MINO™; Aerocrine, Stockholm, Sweden) according to 
American Thoracic Society/European Respiratory Soci- 
ety guidelines [41]. The NIOXMINO™ is pre-calibrated 
for the predetermined life-span of the device and relies 
on built-in flow control with audio and visual feedback 
to maintain flow rates at 50 ± 5 ml/s. After a deep inha- 
lation of NO-free air via an integrated NO-filter the sub- 
jects slowly exhaled over 10 s at the required flow rate. 
Measurements were repeated twice at short intervals of 1 
- 2 min. 
Spirometry was performed according to the recom- 
mendations by the American Thoracic Society [42]. 
Forced expiratory volume in one second (FEV1) was 
measured using a spirometer (Masterlab, Jaeger, Würz- 
burg, Germany) with the patient seated and wearing a 
nose clip. The best of 3 technically acceptable FEV1 
manoeuvres was recorded. FEV1 values were expressed 
as percent predicted according reference data [43]. 
Bronchial hyper-responsiveness (BHR) to mannitol. 
Dry powdered mannitol was supplied in kit form (Ari- 
dol™, Pharmaxis Ltd., Frenchs Forest, NSW, Australia) 
and contained one empty capsule (placebo), 1 × 5 mg, 1 
× 10 mg, 1 × 20 mg and 15 × 40 mg capsules adminis- 
tered using the Osmohaler™ dry powder inhaler (Plas- 
tiape, Osnago, Italy). FEV1 was measured 60 s after each 
mannitol dose (0, 5, 10, 20, 40, 80, 160, 160, 160 mg). 
The 80 mg and 160 mg doses were given in multiples of 
40 mg capsules. The subject was asked to inhale from the 
device and to hold his breath for 5 s. 60 s after inhalation 
of the empty capsule (Placebo), the FEV1 was measured 
twice and the highest of these values was taken as the 
baseline FEV1 and was used to calculate the FEV1 de- 
cline in response to the mannitol challenge. This proce- 
dure was repeated for each dose step until a 15% decline 
in FEV1 was achieved (PD15; positive MDP-test) or a 
cumulative dose of 635 mg had been administered 
[44,45]. 
Quality of life. Quality of life was assessed twice by 
the disease-specific paediatric asthma quality-of-life 
questionnaire (PAQLQ) [46]. Both the self-administered 
(PAQLQ) version and the interviewer-administered 
(PAQLQi) questionnaire were used with the PAQLQ 
always applied first. Both questionnaires are composed 
of the same questions. The questionnaire consists of 23 
questions grouped in three domains: symptoms, activity 
and emotional function. The symptom domain is com- 
posed of 10 questions, the activity domain is composed 
of 5 questions and the emotional function domain con- 
sists of 8 questions. The responses for each item are 
demonstrated on a 7-point scale, where 1 represents se- 
vere impairment and 7 represents no impairment.  
Asthma control. The asthma control test (ACT™) 
was used to assess asthma control [8]. The test contains 
five questions. Each question is scored from 0 (maxi- 
mum impairment) to 5 (no impairment). The sum of 
points of the single questions is added on to the total 
symptom score with a minimum of 0 and a maximum of 
25 points.  
Randomization. A well-trained lung-function techni- 
cian blinded to the treatment decisions performed all 
above-mentioned assessments. The patients were then 
randomly assigned to one of three monitoring groups 
(group 1 FeNO, group 2 mannitol and group 3 spi- 
rometry). According to the test results and the group the 
child was assigned to, one of the investigators (BK; JHW) 
informed the responsible paediatrician of the asthma 
clinic, which was blinded for the test results, on how 
treatment had to be adapted. The dose of ICS was dou- 
bled in group 1 when FeNO was >22 ppb, in group 2 in 
case of a positive MDP-test and in group 3 when FEV1 
was <80% of predicted, respectively, or was maintained 
in the remaining subjects. 
Statistical analysis. Data were analysed using SPSS 
16.0 (SPSS Inc., Chicago, Illinois, USA). Results are ex- 
pressed as mean and standard deviation (SD) or median 
and interquartile range (IQR) in the case of non-normally 
distributed data. Differences between groups at visit 1 
were analysed with the students t-test or non-parametric 
Mann-Whitney U test for independent samples. Changes 
during the intervention between visit 1 and visit 2 were 
analysed with paired t-test or Wilcoxon signed rank test, 
where appropriate. Differences in categorical variables 
between the two groups were analysed by the Chi2-test. 
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Correlation analyses were performed using the Pearson 
correlation coefficient or Spearman rank order. A p- 
value of <0.05 was considered significant. 
3. RESULTS 
60 children were enrolled in the study and randomized. 
Twelve subjects were excluded from the final analyses 
for the following reasons: five individuals experienced 
an exacerbation of their asthma due to acute viral airway 
infection (two in groups 1 and 2, and one subject in 
group 3, respectively), five others did not adhere to the 
treatment recommendations and two were lost for fol- 
low-up. A total of 48 patients successfully completed the 
study (16 per group). Patient characteristics at baseline 
are summarized in Table 1. 
Baseline comparison. When children were grouped 
according to their baseline FeNO values, individuals 
with elevated FeNO (≥22 ppb) had reduced quality of 
life (PAQLQ: 146 ± 8.6 vs 154 ± 5.2; p < 0.001 and 
PAQLQi: 146.4 ± 8.6 vs 154.7 ± 5.8; p < 0.001, respec- 
tively) and lower asthma control (20.8 ± 1.9 vs 23.5 ± 
1.2; p < 0.001) (Figures 1(a)-(c)). Whilst showing a 
similar FEV1 (94.1% ± 12.1% vs 95.6% ± 13.6%; p = 
0.6), these subjects also had lower MEF50 (78.7% ± 
21.7% vs 90.3% ± 15.0%; p = 0.038). 
Of the children with FeNO ≥ 22 ppb, 24 out of 25 
(96%) showed a positive mannitol challenge compared to 
only 3 out of 23 (13%) with FeNO < 22 ppb (p < 0.001) 
(Figure 1(d)). Subjects with a positive MDP-test had 
significantly higher FeNO values compared to children 
with a negative challenge (median [IQR]: 31 [20.5] vs 8 
[12.25]; p < 0.001) (Figure 2(a)). They also showed 
lower quality of life (PAQLQ: 147 ± 8.4 vs 154 ± 5.4; p 
< 0.001 and PAQLQi: 148.5 ± 5.3 vs 155.5 ± 5.7; p < 
0.001, respectively) and lower asthma control (21.0 ± 1.9 
vs 23.5 ± 1.3; p < 0.001) (Figures 2(b)-(d)). Subjects  
 
Table 1. Patient characteristics at baseline visit. 
 Group 1 (FeNO) 
Group 2 
(mannitol) 
Group 3 
(spirometry) p-value 
Age(years) 10.9 ± 2.7 10.0 ± 2.9 10.8 ± 2.7 0.59 
FeNO(ppb) 
20 [31]§ 
22.4 ± 15.9* 
18.5 [26.5] 
21.7 ± 15.9 
22 [15.5] 
22.1 ± 11.7 0.95 
MDP-test(pos/neg) 9/7 (56.3%) 8/8 (50%) 9/7 (56.3%) 0.92¶ 
FEV1(%pred) 95.4 ± 12.8 94.1 ± 16.4 93.7 ± 13.2 0.94 
MEF 50(%pred) 87.3 ± 20.3 84.9 ± 24.1 78.3 ± 17.8 0.456 
PAQLQscore 150.4 ± 9.2 150.6 ± 8.5 150.3 ± 6.5 0.996 
PAQLQiscore 151.6 ± 7.1 149.4 ± 8.7 151.4 ± 5.7 0.622 
ACTscore 22.4 ± 2.1 22.4 ± 2.1 21.6 ± 2.1 0.513 
*mean ± standard deviation (SD); §median [IQR]; ¶chi2 test. 
with a negative MDP test showed higher peripheral 
forced flows (MEF50) as compared to children with 
BHR (91.3% ± 13.6% vs 78.8% ± 21.8%; p = 0.026), 
whereas there was no difference in FEV1 (94.7% ± 
12.3% vs 94.9% ± 13.2%; p = 0.95).  
Intervention. At the first visit, 8 out of 16 (50%) chil- 
dren from group 1 (FeNO) showed FeNO levels > 22 
ppb, in group 2, (BHR) 8 children out of 16 (50%) 
showed a positive MDP-test and in group 3 (spirometry), 
3 children out of 16 (18.7%) had a FEV1 < 80% of pre- 
dicted and had their ICS-dose doubled. There were no 
significant differences between the three groups regard- 
ing the assessments at visit 1. In group 1, FeNO de- 
creased significantly between visit 1 and visit 2 (p = 
0.005), whereas the self-administered PAQLQ score (p = 
0.02), the interviewer-administered PAQLQ(i) score (p = 
0.033) and the asthma control test (ACT; p = 0.031) in- 
creased significantly. Neither the number of children 
with a positive mannitol challenge (p = 0.72) nor the 
spirometricparameter (FEV1: p = 0.211; MEF50: p = 
0.083) changed significantly (Figures 3(a)-(d) and Ta- 
ble 2). In group 2 (mannitol) and group 3 (spirometry) 
there were no significant changes in the objective pa- 
rameters, such as FeNO, spirometry and the number of 
children with positive mannitoltests, and no significant 
changes in the quality of life scores nor in the asthma 
control test (Table 2). 
Correlations. Significant negative correlations were 
found for FeNO and quality of life (PAQLQ score: cc 
−0.65; p < 0.001 and PAQLQ(i) score: cc −0.51; p < 
0.001) and a strong negative correlation for FeNO and 
ACT score (cc −0.77; p < 0.001) (Figures 4(a)-(c)). 
MEF50%pred was weakly correlated to FeNO (cc −0.422; 
p = 0.0029; data not shown), whereas there was no sig- 
nificant correlation between FeNO and FEV1%pred (cc 
−0.28; p = 0.054) (Figure 4(d)). The asthma control test 
was significantly correlated with both the self-adminis- 
tered PAQLQ score and the interviewer-administered 
PAQLQ(i) (cc 0.61; p < 0.001 and cc 0.55; p < 0.001, 
respectively). In addition, there were weak but signifi- 
cant relationships between the asthma control score and 
lung function (FEV1%pred: cc 0.29; p = 0.041 and 
MEF50%pred: cc 0.46; p = 0.0011, respectively). 
4. DISCUSSION 
According to current guidelines for the management of 
asthma in schoolchildren, treatment guidance is mainly 
based on reported symptoms [47]. If asthma control is 
insufficient, the anti-inflammatory treatment is stepped 
up, whereas the dose will remain unchanged or be re- 
duced when good asthma control is achieved. However, 
asthma control was found to be insufficient with signify- 
cant impact on the daily life in the majority of children in 
several previous European studies [5,10]. Studies as-  
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Figure 1. Relationships between FeNO levels and quality of life, asthma control and the results of the MDP test at 
baseline. (a, b) Quality of life scores at baseline grouped according to FeNO values; (c) Asthma control scores at 
baseline grouped according to FeNO values. The median is the line bisecting the box, the box limits represent 25th 
and 75th percentiles and whiskers extend to the 10th and 90th percentile, whereas the black dots represent outliers; 
(d) Percentage of children with positive and negative MDP-test grouped according to FeNO values at baseline. Black 
bar indicates children with a positive MDP-test, white bar children with a negative MDP-test. PAQLQ = Pediatric 
Asthma Quality of life questionnaire; PAQLQi = interview based Pediatric Asthma Quality of life questionnaire; 
FeNO: Fractional exhaled nitric oxide; ACT: Asthma Control Test; MDP: mannitol dry powder provocation test. 
 
Table 2. FeNO, MDP test, FEV1, PAQLQ, PAQLQi and ACT for the three groups at visit 1 and visit 2. 
Group 1 (FeNO) Group 2 (mannitol) Group 3 (spirometry) 
 
Visit 1 Visit 2 p-value Visit 1 Visit 2 p-value Visit 1 Visit 2 p-value
FeNO§(ppb) 20 [5-36] 5 [5-19] 0.005 18.5 [7.5-34] 18.5 [15-28] 0.847 22 [15-30.5] 16.5 [11-31] 0.417 
MDP test (pos/neg) 9/7 7/9 0.720 8/8 9/7 0.802 9/7 8/8 0.802 
FEV1*(%pred) 95.4 ± 12.8 98.1 ± 8.6 0.21 94.1 ± 16.4 94.6 ± 15.3 0.857 93.7 ± 13.2 94.1 ± 12.2 0.813 
MEF50*(%pred) 87.3 ± 20.2 94.3 ± 13.3 0.083 84.9 ± 24.1 84.8 ± 24.6 0.98 78.3 ± 17.8 76.9 ± 16.4 0.637 
PAQLQ* 150.4 ± 9.2 154.9 ± 4.8 0.02 150.5 ± 8.4 150.7 ± 7.9 0.924 150.3 ± 6.5 150.7 ± 5.6 0.764 
PAQLQ(i)* 151.6 ± 7.1 154.7 ± 4.1 0.033 149.4 ± 8.7 149.8 ± 8.9 0.767 151.4 ± 5.5 151.9 ± 6.0 0.719 
ACT* 22.4 ± 2.1 23.5 ± 1.2 0.031 22.3 ± 2.1 22.9 ± 2.2 0.406 21.6 ± 2.1 22.0 ± 2.5 0.347 
§median [IQR]; *mean ± standard deviation (SD). 
 
sessing treatment titration based on objective measures 
of airway inflammation determined by the means of 
FeNO gave controversial results [17,29-31]. We per- 
formed a randomized, prospective, double blinded study 
to investigate the impact of treatment guidance based on 
FeNO, BHR to mannitol, or spirometry on quality of life, 
asthma control and airway inflammation. Treatment 
uidance based on FeNO led to significant improvements  g 
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Figure 2. FeNO levels quality of life and asthma control in children with positive and negative MDP tests at baseline. 
(a) FeNO values of children with positive and negative MDP tests; (b, c) Quality of life scores at baseline grouped 
according to the results of the MDP test at baseline; (d) Asthma control scores at baseline grouped according to the 
results of the MDP test at baseline. The median is the line bisecting the box, the box limits represent 25th and 75th 
percentiles and whiskers extend to the 10th and 90th percentile, whereas the black dots represent outliers. PAQLQ = 
Pediatric Asthma Quality of life questionnaire; PAQLQi = interview based Pediatric Asthma Quality of life ques- 
tionnaire; FeNO: Fractional exhaled nitric oxide; ACT: Asthma Control Test; MDP: mannitol dry powder provo- 
cation test. 
 
in asthma control and quality of life, and to a reduction 
of airway inflammation as expressed by FeNO. This was 
in contrast to the children in whom treatment was 
adapted according to FEV1 levels or the presence of 
BHR to mannitol. In our study, ICS dose was doubled 
when FeNO was elevated (≥22 ppb) indicating airway 
inflammation, or remained unchanged in children with 
normal levels (<22 ppb). This cut-off value was based on 
available normative data [19,41]. In the spirometry group 
ICS dose was doubled when FEV1 was <80% predicted, 
as suggested by current guidelines [47,48], or in the 
presence of BHR to mannitol, in the BHR group, respec- 
tively. Only three children in the spirometry group had 
FEV1 values < 80% of predicted which clearly limits 
statistical analysis.  
FEV1 is within the accepted normal range in most 
school children independent of their asthma severity, 
when defined on the basis of symptoms [13,49]. The ma- 
jority of asthmatic children attending a tertiary care facil- 
ity have FEV1 values within the normal range [49]. This 
indicates that the cut-off values may not adequately 
stratify asthmatic children [13,49].  
Concerning spirometry it has been shown that in chil- 
dren FEV1 and individual symptom scores or clinical 
disease severity have no significant correlation [12,13,50, 
51], and only a weak correlation was found for FEV1/ 
FVC and symptom scores [12,13]. Hence, it appears that 
the current guidelines for asthma management may lead 
to sub-optimal control of the disease [4]. These findings 
indicate that not only symptoms and spirometry may be 
considered for managing asthma treatment but also other 
objective parameters, such as BHR and airway inflam- 
mation. 
BHR to a variety of stimuli is a key feature of asthma 
and is an important determinant of asthma prognosis and 
lung function development in childhood [52,53]. Grol et 
al. found that low FEV1 and severe BHR in childhood 
are independent risk factors for reduced FEV1 in young  
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Figure 3. Results for the three groups at baseline and after three months. Results for the different management groups at 
visit 1 and 2. The ICS dose was adapted according to FeNO values (FeNO group), the result of the MDP-test (mannitol 
group) of FEV1 (spirometry group). (a) FeNO values at visit 1 and 2. 3 (b, c) quality of life assessed by the PAQLQ at 
visit 1 and 2; (d) Asthma control at visit 1 and 2. The median is the line bisecting the box, the box limits represent 25th 
and 75th percentiles and whiskers extend to the 10th and 90th percentile, whereas the black dots represent outliers. FeNO 
decreased, PAQLQ and ACT scores increased in the FeNO group only. PAQLQ = Pediatric Asthma Quality of life ques- 
tionnaire; PAQLQi = interview based Pediatric Asthma Quality of life questionnaire; FeNO: Fractional exhaled nitric 
oxide; ACT: Asthma Control Test; MDP: mannitol dry powder provocation test. 
 
adulthood [54]. Therefore, in order to achieve optimal or 
total asthma control, it could be expected that the meas- 
urement of BHR in asthmatic children on a regular basis 
would be helpful. However, BHR challenge tests have 
some disadvantages that have to be taken into account: 
they are difficult to perform in younger children, are time 
consuming, and come with certain risks [55]. In addi- 
tion, it has been shown that BHR shows only a slow re- 
sponse to modifications of inhaled corticosteroid therapy 
and so is not an ideal tool for short term treatment guid- 
ance [14-16]. A study by Nuijsink et al. has demon- 
strated that a treatment strategy guided by airway hy- 
per-responsiveness over a 2-year period in 210 atopic 
asthmatic children had no benefits in terms of number of 
symptom-free days but resulted in a better outcome of 
pre-bronchodilator FEV1 [11]. Sont et al. showed that a 
treatment strategy including BHR determination leads to 
a lower rate of mild exacerbations, higher FEV1, greater 
reduction in thickness of the subepithelial reticular layer 
in bronchial biopsies but was associated with higher ICS  
doses in asthmatic allergic adults [4].  
Asthma is considered to be primarily an inflammatory 
disease of the airways; allergic asthma in particular 
shows an eosinophilic inflammation. Therefore it can be 
argued that an objective parameter of eosinophilic airway 
inflammation, which correlates to symptoms and shows a 
fast response on changing disease control, would be a 
valuable tool in diagnosing and managing asthma. It has 
been shown that FeNO is a non-invasive marker of eosi- 
nophilic airway inflammation [57-59] and measurement 
of FeNO can be of help in diagnosing allergic asthma 
[23,25,56]. FeNO can be used to predict clinical outcome 
in terms of steroid response and exacerbations. Little et 
al. [26] have shown that asthmatic adults with elevated 
FeNO levels had a benefit from an increase in the ICS 
dose. With ICS treatment FeNO decreases in asthmatics 
in a dose dependent manner. It has therefore been sug- 
gested that FeNO might serve as a sensitive inflamma- 
tory marker for assessing treatment response [20,21]. In 
addition elevated FeNO predicts asthma relapse after  
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L. M. Patrick et al. / Open Journal of Pediatrics 3 (2013) 406-417 413
  
 
Figure 4. Correlations between FeNO and quality of life, asthma control and lung function. (a, b) Correlations between base-
line FeNO values and quality of life scores; (c) Correlation between asthma control score and FeNO; (d) Correlation between 
FEV1 and FeNO. There was a significant negative correlation between FeNO values PAQLQ scores and ACT scores but not 
correlation between FeNO and FEV1. cc = correlation coefficient; PAQLQ = Pediatric Asthma Quality of life questionnaire; 
PAQLQi = interview based Pediatric Asthma Quality of life questionnaire; FeNO: Fractional exhaled nitric oxide; ACT: 
Asthma Control Test. 
 
discontinuation or reduction of steroids in adults and 
children [18,19]; furthermore, FeNO shows a fast re- 
sponse to treatment modification [14,28].  
Several studies in asthmatic adults and children inves- 
tigated the usefulness of FeNO to guide therapy with 
contrasting results. Shaw et al. found that an asthma 
treatment strategy in asthmatic adults based on FeNO 
levels was feasible but did not result in a significant re- 
duction in asthma exacerbations [35]. These results are 
consistent with findings by Smith et al. [30] in adults and 
Pijnienburg et al. [17] and Pike et al. [33] in children. 
Due to the short study duration we did not see differ- 
ences in asthma exacerbations in our study. There are 
also conflicting results in these studies regarding the ef- 
fect of FeNO-based ICS treatment titration compared to 
a control group treated according to current guidelines. 
Whereas Smith et al. showed a significant decrease in 
maintenance dose of ICS without compromising asthma 
control [30], Shaw et al. did not observe a reduction in 
the total amount of ICS used. Nevertheless, participants 
of the FeNO-guided group were on a lower ICS dose at 
the end of the study compared to the control group [29]. 
In contrast, Szefler et al. demonstrated that adding FeNO 
measurement to standard care did not result in significant 
improvement in asthma control but in higher ICS doses 
in asthmatic inner-city adolescents and young adults [31]. 
De Jongste et al. found similar results in asthmatic chil- 
dren [57]. Most recently, Pike et al. demonstrated that 
FENO-guided ICS titration did not reduce corticosteroid 
usage or exacerbation frequency in paediatric outpatients 
with moderate to severe asthma when compared to con- 
ventional asthma management [33]. 
In a study including 85 atopic asthmatic schoolchil- 
dren, Pijnenburg et al. showed that titration of ICS 
treatment based on FeNO led to a decrease in BHR and 
airway inflammation, but did not result in better asthma 
symptom control [17]. In our study we observed a sig- 
nificant decrease in FeNO and increased asthma control 
(ACT) as well as an increased quality of life (PAQLQ) in 
the FeNO guided group. One reason may be, on the one 
hand, the lower cut-off value for FeNO in our study (22 
ppb), which allowed an earlier increase of ICS treatment 
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that might have resulted in a better control of airway 
inflammation. On the other hand, our study population 
was characterized by children with milder asthma on a 
relatively low ICS dose at study entry (200 mcg 
budesonide-equivalent), in opposite to others who in- 
cluded more severely affected subjects. 
In contrast to other studies we did not observe a 
change in the number of children with a positive manni- 
tol challenge. This is likely due to various reasons. First, 
the study duration of only 3 months was shorter than in 
other studies with durations between 6 to 24 months 
[4,11,17] and might have been too short to reduce BHR 
significantly. It has previously been demonstrated that 
BHR shows a slow response to modification of ICS 
therapy [14]. Second, in other studies either methacho- 
line [4,11,17] has been used as the provocative agent. An 
important limitation of our data is the fact that we were 
not able to analyse response slopes, as only the final test 
result (positive and negative, respectively) was available 
for further analysis. In contrast to previous studies that 
evaluated the value of treatment guided by FeNO in ad- 
dition to symptoms or symptom guided treatment [17,29, 
31,57] we adapted the ICS therapy on objective meas- 
urements only, i.e. FEV1, BHR to mannitol and FeNO.  
Children with elevated FeNO had lower quality of life 
scores and lower ACT scores, with a high inverse corre- 
lation between FeNO and the PAQLQ scores or the ACT 
score, respectively. Such relationships have been de- 
scribed in previous studies. A similar correlation be-
tween the ACT scores and FeNO in asthmatic children 
has been found in two studies [27,40], and Roberts et al. 
showed a clear negative correlation between the PAQLQ 
and FeNO [58]. However, other studies failed to find 
such relationships [13,59,60]. It remains unclear whether 
symptoms, and in consequence asthma related quality of 
life, is directly linked to airway inflammation as reflected 
by FeNO, or if these parameters measure independent 
factors.  
Interestingly, FeNO was also associated with BHR to 
mannitol. 24 out of 25 of the children with FeNO > 22 
ppb showed a positive mannitol challenge, compared to 
13% of children with lower FeNO levels. Therefore, the 
sensitivity of FeNO > 22 ppb to predict a positive MDP 
was 96% with a specificity of 87%. A similar relation- 
ship between FeNO and BHR to mannitol was found by 
Decimo et al. [61]. 
5. CONCLUSION 
In conclusion, we have shown that there is a close re- 
lationship between elevated FeNO levels and bronchial 
hyper-responsiveness to mannitol. Children with ele- 
vated FeNO had lower quality of life scores and lower 
asthma control. Children with a positive MDP test had 
lower asthma quality of life and lower asthma control. 
Taken together, we demonstrated that ICS dose modifi- 
cation based on FeNO led to increased quality of life and 
asthma control and a reduction in airway inflammation 
and was superior to treatment changes based on BHR to 
mannitol or on FEV1. 
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